Literature DB >> 18981170

Epidemiology and costs associated with genital warts in Canada.

F Marra1, G Ogilvie, L Colley, E Kliewer, C A Marra.   

Abstract

BACKGROUND: Genital warts (condyloma acuminatum) remain one of the most commonly reported sexually transmitted infections (STI) worldwide. Most genital warts are caused by non-oncogenic human papilloma virus. Recurrence is common and many patients receive several rounds of treatment. There are limited data in the literature on the burden of illness and costs associated with genital warts at a population level.
METHODS: Episodes of anogenital warts (AGW) were identified from the physician billing database, hospitalisation records and STI clinics from 1998 to 2006. To be included from the physician billing and STI databases, the person had to have a claim that had a diagnosis of condyloma acuminatum (078.11), viral warts (078.1), viral warts unspecified (078.10) or other unspecified warts (078.19), as well as one of the relevant fee codes associated with the treatment of AGW. To be included from the hospital database, the person could be of any age and have a diagnosis of AGW (A63.0), condyloma acuminatum (078.11), viral warts (078.1 or B07), viral warts unspecified (078.10) or other unspecified warts (078.19) in any of the diagnosis fields, as well as one of the relevant procedure codes associated with the treatment of AGW.
RESULTS: A total of 39,493 people was diagnosed with AGW and during this period they had a total of 43,586 episodes. The average cost per episode of AGW was $C190 ($C176 for men; $C207 for women). The majority of treatment was with ablative therapy alone (98%).
CONCLUSIONS: AGW are associated with a significant burden of illness and costs to the healthcare system.

Entities:  

Mesh:

Year:  2008        PMID: 18981170     DOI: 10.1136/sti.2008.030999

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  26 in total

1.  Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) .

Authors:  Dr M Dawar; Ms T Harris; Dr S McNeil
Journal:  Can Commun Dis Rep       Date:  2012-01-02

2.  Human papillomavirus vaccination for boys.

Authors:  Stephany Quinn; Ran D Goldman
Journal:  Can Fam Physician       Date:  2015-01       Impact factor: 3.275

Review 3.  Economic and humanistic burden of external genital warts.

Authors:  Adam J N Raymakers; Mohsen Sadatsafavi; Fawziah Marra; Carlo A Marra
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

4.  Incidence of genital warts among the Hong Kong general adult population.

Authors:  Chunqing Lin; Joseph T F Lau; King-Man Ho; Man-Chun Lau; Hi-Yi Tsui; Kuen-Kong Lo
Journal:  BMC Infect Dis       Date:  2010-09-17       Impact factor: 3.090

Review 5.  Human papillomavirus (HPV) infection: a Mozambique overview.

Authors:  Damiano Pizzol; Giovanni Putoto; Kajal D Chhaganlal
Journal:  Virusdisease       Date:  2016-05-03

6.  Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.

Authors:  Kristina R Dahlstrom; Shuangshuang Fu; Wenyaw Chan; Zeena Shelal; Lois M Ramondetta; David R Lairson
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

7.  Incidence of anogenital warts in Germany: a population-based cohort study.

Authors:  Angela A Kraut; Tania Schink; Renate Schulze-Rath; Rafael T Mikolajczyk; Edeltraut Garbe
Journal:  BMC Infect Dis       Date:  2010-12-23       Impact factor: 3.090

8.  Genital warts and cost of care in England.

Authors:  Sarika Desai; Sally Wetten; Sarah C Woodhall; Lindsey Peters; Gwenda Hughes; Kate Soldan
Journal:  Sex Transm Infect       Date:  2011-08-03       Impact factor: 3.519

Review 9.  Systematic review of the incidence and prevalence of genital warts.

Authors:  Harshila Patel; Monika Wagner; Puneet Singhal; Smita Kothari
Journal:  BMC Infect Dis       Date:  2013-01-25       Impact factor: 3.090

10.  Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.

Authors:  Michele Kohli; Donna Lawrence; Jennifer Haig; Andrea Anonychuk; Nadia Demarteau
Journal:  BMC Public Health       Date:  2012-10-13       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.